Agile Therapeutics, Inc. (AGRX)
| Market Cap | 159.48M |
| Revenue (ttm) | 749,000 |
| Net Income (ttm) | -51.85M |
| Shares Out | 84.68M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $1.82 |
| Previous Close | $1.84 |
| Change ($) | -0.02 |
| Change (%) | -1.09% |
| Day's Open | 1.83 |
| Day's Range | 1.75 - 1.86 |
| Day's Volume | 1,377,700 |
| 52-Week Range | 1.75 - 3.89 |
PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will pres...
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available
Live Conference Call and Webcast at 4:30 p.m. ET
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participat...
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healthca...
Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA approved p...
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)
PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, reproductiv...
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will par...
The drugmaker will soon give Twirla a twirl.
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2020 Results - Earnings Call Transcript
Commercial Launch of Twirla® Expected by Year-End 2020
Live Conference Call and Webcast at 4:30 p.m. ET
PRINCETON, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually presentin...
PRINCETON, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executi...
Company to Present Twirla® Commercial Plan
Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options
PRINCETON, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD, MBA, to t...
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q2 2020 Results - Earnings Call Transcript
PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will p...
Live Conference Call and Webcast at 4:30 p.m. ET
Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
PRINCETON, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® and 2000® ...
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2020 Results - Earnings Call Transcript
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
Agile's shares are heating up ahead of the company's Q1 earnings report.
Agile Therapeutics: Billion Dollar Buy-Out Is On The Horizon
PRINCETON, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon Barbar...
Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
The biotech stock is getting hit hard by the marketwide downturn today. Here's why.
Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.
Shares drop after the company releases the pricing details of a recently announced capital raise.
Agile Therapeutics (AGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is (AGRX) Outperforming Other Medical Stocks This Year?
PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million ...
PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock i...
Twirla now has a green light from the FDA. And that could mean a green light for investors looking for a promising small-cap biotech stock.
Agile Therapeutics Inc. (NASDAQ: AGRX) shares took a dip on Tuesday after the company announced a key U.S.
Agile Could Reach $10/Share After Twirla Approval
Coronavirus is having a major impact across sectors.
Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S.
The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.
Bargain-seeking investors might want to look at these three stocks before venturing into the risky world of penny stocks.
Funding to Support the Company’s Commercialization Plans for Twirla ®
Short-Term Catalyst And Long-Term M&A Potential Make Agile Therapeutics An Attractive Potential Takeover Target
About AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a reg... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date May 23, 2014 |
| CEO Alfred Altomari | Employees 28 |
| Stock Exchange NASDAQ | Ticker Symbol AGRX |
Analyst Forecasts
According to 5 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is 8.25, which is an increase of 353.30% from the latest price.